Synapse - Thoracic Oncology

Results (3351)

Brief report: Clinical characteristics and outcomes of patients with thoracic SMARCA4-deficient undifferentiated tumors

Journal Article

Cooper, A. J.; Arfe, A.; Ricciuti, B.; Gagné, A.; Sholl, L. M.; Di Federico, A.; Awad, M. M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; more...
JTO Clinical and Research Reports (2025)

Fulltext@MSK | Save

Combining a WT1 vaccine (Galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1–expressing diffuse pleural mesothelioma: A phase 1 study

Journal Article

Agrawal, P.; Offin, M.; Lai, V.; Ginsberg, M. S.; Adusumilli, P. S.; Rusch, V. W.; Sauter, J. L.; Ho, T.; Wong, P.; Zauderer, M. G.
JTO Clinical and Research Reports (2025)

Fulltext@MSK | Save

Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer

Journal Article

Robles-Oteíza, C.; Hastings, K.; Choi, J.; Sirois, I.; Ravi, A.; Expósito, F.; de Miguel, F.; Knight, J. R.; López-Giráldez, F.; Choi, H.; more...
Journal of Experimental Medicine (2025)

Fulltext@MSK | Save

Matching-adjusted indirect comparison (MAIC) of safety outcomes with MET tyrosine kinase inhibitors (TKIs) in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)

Meeting Abstract

Taylor, K.; Veillon, R.; Griesinger, F.; Reinmuth, N.; Ghori, V.; Vioix, H.; Clark, A.; Paik, P.
Value in Health (2024)

Fulltext@MSK | Save

Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study

Meeting Abstract

Johnson, M. L.; Simoes da Rocha, P. F.; Kim, Y. J.; Chen, Y.; Paz-Ares, L. G.; Girard, N.; Hann, C. L.; Nishio, M.; Ahn, M. J.; Qian, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)

Meeting Abstract

Rudin, C. M.; Salkeni, M. A.; Gutierrez, M.; Hayashi, H.; Thompson, J.; Arca, M.; Hirose, D.; Singh, J.; Turner, J.; Zhang, Y.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004

Meeting Abstract

Cobb, P. W.; Hochmair, M.; Schuler, M. H. H.; Riely, G. J.; Rojas, C. I.; Kim, S. J.; Chen, X.; Lara-Guerra, H.; Felip, E.
Annals of Oncology (2024)

Fulltext@MSK | Save

Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials

Meeting Abstract

Skoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van Der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)

Meeting Abstract

Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
Annals of Oncology (2024)

Fulltext@MSK | Save

METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study

Meeting Abstract

Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save